Hughes A, Thom S, Martin G, Redman D, Hasan S, Sever P
Br J Clin Pharmacol. 1986 Nov;22(5):535-40. doi: 10.1111/j.1365-2125.1986.tb02932.x.
This study was designed to investigate dopaminergic mechanisms in human vasculature using the selective vascular dopamine receptor agonist fenoldopam in vivo and in vitro. In vivo, forearm blood flow was measured plethysmographically and in vitro isolated rings of human blood vessels from a variety of sites were used for tissue bath studies. Intra-arterial fenoldopam markedly increased forearm blood flow, this effect was antagonised by (R) sulpiride, a vascular dopamine (DA1) antagonist, but not by metoclopramide, a neuronal (DA2) antagonist, or by guanethidine, an adrenergic neurone blocking agent. In vitro, fenoldopam relaxed preconstricted human renal, mesenteric and lumbar arteries, but not saphenous vein in a concentration dependent manner. (RS) sulpiride and SCH 23390 competitively antagonised this effect. These studies demonstrate the presence of a vasodilatory vascular dopamine receptor in man both in vivo and in vitro.
本研究旨在利用选择性血管多巴胺受体激动剂非诺多泮，在体内和体外研究人体血管中的多巴胺能机制。在体内，通过体积描记法测量前臂血流量；在体外，使用从多个部位获取的人体血管离体环进行组织浴研究。动脉内注射非诺多泮可显著增加前臂血流量，这种效应可被血管多巴胺（DA1）拮抗剂（R）舒必利拮抗，但不能被神经元（DA2）拮抗剂甲氧氯普胺或肾上腺素能神经元阻断剂胍乙啶拮抗。在体外，非诺多泮以浓度依赖性方式使预先收缩的人肾动脉、肠系膜动脉和腰动脉舒张，但对隐静脉无此作用。（RS）舒必利和SCH 23390竞争性拮抗此效应。这些研究表明，人体体内和体外均存在血管舒张性血管多巴胺受体。
